1 / 8

Trial profile

Trial profile. Mann JF et al. Lancet 2008;372:547-53. Decrease in estimated glomerular filtration rate (eGFR) during the trial, from baseline to study end. Mann JF et al. Lancet 2008;372:547-53. Estimated glomerular filtration rate at baseline and changes of eGFR.

sorena
Télécharger la présentation

Trial profile

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial profile Mann JF et al. Lancet 2008;372:547-53

  2. Decrease in estimated glomerular filtration rate (eGFR) during the trial, from baseline to study end Mann JF et al. Lancet 2008;372:547-53

  3. Estimated glomerular filtration rate at baseline and changes of eGFR Mann JF et al. Lancet 2008;372:547-53

  4. Incidence of primary and secondary renal outcomes and of its components Mann JF et al. Lancet 2008;372:547-53

  5. Kaplan-Meier curves for (A) primary renal outcome (dialysis, doubling of serum creatinine, and death), (B) secondary renal outcome (dialysis and doubling of serum creatinine), and (C) dialysis T=telmisartanR=ramipril Mann JF et al. Lancet 2008;372:547-53

  6. Relative risk for primary renal outcome in subgroups (A) Comparison of ramipril and telmisartanThe interaction term tests whether there is an interaction of the subgroup with the two treatment modalities Mann JF et al. Lancet 2008;372:547-53

  7. Relative risk for primary renal outcome in subgroups (B) Comparison of ramipril and telmisartan plus ramipril The interaction term tests whether there is an interaction of the subgroup with the two treatment modalities Mann JF et al. Lancet 2008;372:547-53

  8. Changes in log urine albumin to creatinine ratio Mann JF et al. Lancet 2008;372:547-53

More Related